Gilead Sciences, Inc. (GILD)

I like the statistics about this company, a good margin, effective management numbers good roi and roic, i dont see a lot not to like, except that it operates from within the veil of the great OZ (or one of them) the FDA) haha.

A recession proof business. Leader in HIV /Aids treatment.Good products in the works for hypertension, liver fibrosis, and chrohic hepatitis c. Solid balance sheet.

This stock unfortunately gets punished every time it reports strong profits, the recovers......

This stock has languished while other sectors have driven the market. It is relatively inexpensive at the moment. Low peg, favorable pe, strong growth, low debt, and strong free cash flow. Given the connection to tamiflu, I think as swine flu continues to terrorize here in the midwest and elsewhere, it could have a real strong quarter or two.

I'm not much into purchasing the large and mega caps because a double is most likely the top of the run even for a growth machine like this one, and I'm also addicted to the longshots, but for the simple man just looking to turn a profit. Here she is. Buy $30 to $35 it most likely won't add very many points in your caps account as it slowly rises in dollars to the $50 or $60 range because caps does not register points from dollar gains but more so from daily S&P gains or losses compared to the stock.Bought the stock myself Feb 2005 for $17 and held it until may 2008 and it grew like grass. Even as big as it is,still growing like a tree.Beat est 6 out of the last 8 calls and estimates were increased 10/24/09. 2nd quarter 2009 rang in above 38% compared to last years 2nd quarter. P/E 17.00 Forward P/E 14.00 ,PEG 1.0 ,5 year sales growth 43% ,Gross Margins 77.00% , Net Profit Margins 37.00% ,ROE 47.00 Dept/Equity Ratio very low 0, Free cash flow superb. Company already upped full year 2009 guidance on both sales and revenue. I fully invested else where early part of this year and own no shares of this monster anymore,but for those still looking. You may want to give this one a hard look and catch it on the dip.

Solid Company, Unique Product Offering, missed general market rise off lows.

Innovation...superior.

An excellent bio-tech with product out there gaining in revenue while research continues into crucial health care needs.
Balance sheet,Free Cash Flow,Income and Net will continue to improve.

sector change. gold is out. biotech in!

I've owned it since the early 1990's and its been one of my best investments of all time. I used to think it would get acquired by a major pharma.....but now it is one!

Telechart Scan Multi Moving Averages Convergence

One of the best houses in a good neighborhood.

Tamiflu, good profit growth. Even the last two quarters are up slightly over the previous two.

When the flu season starts they will get royalties on Tamiflu. Think of H1N1 coming. Sad but true! This is a great company anyway.

has the management and ability to move-up.

Global need, great RoE, profit margins and cash flow. Makes Tamiflu for treatment of Swine Flu and other drugs for treatment of life threatening infectious diseases including AIDS. Global provider of its medications including the W.H.O. Works with all the top Pharmaceutical companies in its R&D. Should outpace S&P by 60% on average.

As long as GILD's Atripla continues to be the lead choice of a single dose / single pill HIV treatment, it will gain market share as doctors put patients on this drug.

Recent study showing that the company's anti-HIV drugs can be used in Africa without constant lab test monitoring of patients should boost significantly its opportunities in developing markets.

Negatives can be competitors coming up with their own one pill / once-per-day HIV drugs or alternative therapies appearing. Those are still at least few years away.

great co.

Super fantastic fundamentals!

Possible Aids Drug sales in China.